Virus susceptibility and clinical effectiveness of anti- @entity683 drugs during the 2010-2011 XXXX season in Russia.

@entity689 @entity1 @entity684 @entity55 @entity19 @entity683 @entity281 @entity1729 @entity18600
BACKGROUND: Antiviral drugs are critical adjuncts to @entity683 vaccination. This study determined the in vitro susceptibilities of @entity683 A and B viruses isolated in the 2010-2011 season in Russia to the @entity689 inhibitor @entity684 and the hemagglutinin fusion inhibitor @entity18600 and clinical efficacy of this antiviral drugs in this season. METHODS: The antiviral potency of these drugs against A(H1N1)pdm09 virus in @entity19 was assessed. Importantly, the clinical effectiveness of @entity684 and @entity18600 was evaluated in a retrospective study conducted in 26 regions of Russia. RESULTS: All tested viruses (n=36) were susceptible to @entity684 and @entity18600 in vitro. @entity684 (10mg/kg/day) and @entity18600 (60mg/kg/day) significantly increased the survival of @entity19 challenged with A/California/04/2009 (H1N1)pdm09 virus (p<0.05). @entity281 was laboratory-confirmed in 442 @entity1 among 1462 @entity1 hospitalized with @entity1729 . The treatment of @entity281 @entity1 within 48h of symptom onset with @entity684 and @entity18600 was associated with a significant decrease in the duration of illness (2-3 days) and symptoms (p<0.001). @entity55 was observed in none of the @entity1 treated with @entity684 and in 0.3% of the @entity1 treated with @entity18600 , compared to 23.7% of @entity1 who did not receive antiviral therapy (p<0.001). CONCLUSIONS: This study provided experimental and clinical evidence of the efficacy of @entity684 and @entity18600 against @entity683 viruses, representatives of which have continued to circulate in post-pandemic seasons.
